Environmental

Gilead’s R&D intensity near 20% of revenue supports a lower-carbon, science-led operating model versus peers with heavier manufacturing footprints.

The company’s asset-light biopharma profile generally reduces direct emissions and water intensity relative to large-cap pharmaceutical peers with broader production networks.

Limited disclosed capital-intensive environmental exposure suggests fewer transition-cost pressures than peers with larger owned manufacturing and utility dependencies.

Environmental risk remains moderate because pharmaceutical supply chains still face waste, energy, and compliance burdens, but these appear manageable versus peers.

Social

Gilead’s high R&D spend supports patient access and medical innovation, which is a stronger social alignment than peers with lower research commitment.

The company’s low stock-based compensation ratio indicates less dilution pressure on employees and shareholders than many large-cap biotech peers.

As a healthcare company, Gilead faces elevated product-safety and access expectations, but these are industry-wide rather than peer-specific disadvantages.

Social positioning is supported by the public-health relevance of its portfolio, though pricing and access scrutiny remain material across the sector.

Governance

Gilead’s leverage is elevated, with debt-to-equity above 2.2x and net debt-to-EBITDA above 36x, which weakens balance-sheet flexibility versus peers.

The low stock-based compensation ratio supports more disciplined capital allocation than peers that rely heavily on equity-linked pay.

Governance quality is constrained by the capital structure because higher leverage can amplify oversight demands and reduce resilience in adverse scenarios.

Absent evidence of major controversy, governance appears broadly acceptable, but the leverage profile leaves it below stronger large-cap healthcare peers.

Overall Score

Gilead screens as a strong ESG name versus peers, led by favorable environmental and social positioning, while governance is held back by elevated leverage.

Score Driver: High R&D Intensity And An Asset-Light Biopharma Footprint Versus Peers